This category covers biotechnology and pharmaceutical companies developing therapies targeting ferroptosis — an iron-dependent form of regulated cell death characterized by lipid peroxidation accumulation — for the treatment of Alzheimer's disease. Ferroptosis is increasingly recognized as a key mechanism contributing to neuronal loss in AD, with evidence pointing to impaired glutathione peroxidase 4 (GPX4) function, iron dyshomeostasis, and lipid peroxidation accumulation in affected brain regions["@ferroptosis_ad_review"].
Unlike apoptosis or necrosis, ferroptosis is distinctively characterized by:
Iron-dependent accumulation of lipid peroxides
Loss of GPX4 activity leading to membrane lipid damage
Sensitivity to iron chelation and lipid antioxidant treatment
Distinct morphological features (smaller mitochondria, dense membrane)
Companies in this space pursue several mechanisms targeting different nodes of the ferroptosis pathway, including iron chelation, GPX4 activation/inhibition prevention, lipid peroxidation scavenging, and coenzyme Q10 redox augmentation.
Key Mechanisms
Iron Chelation
Reducing labile iron availability that drives Fenton reactions and lipid peroxide formation. Deferiprone and similar BBB-penetrant chelators.
GPX4 Activation
Restoring or enhancing GPX4 function to reduce lipid peroxides. Includes direct GPX4 modulators and upregulation strategies.
Lipid Peroxidation Inhibition
Scavenging lipid peroxyl radicals before they damage membranes. Ferrostatin-1 analogs and lipophilic antioxidants.
CoQ10 Redox Augmentation
FSP1-mediated CoQ10 reduction provides alternative lipid peroxidation defense independent of GPX4.
Key Companies
Clinical-Stage Companies
Vivoryon Therapeutics N.V.
Focus: Glutaminyl cyclase inhibition with secondary ferroptosis modulation
Lead Candidate: Varoglutamstat (PQ912)
Indication: Early Alzheimer's disease
Stage: Phase IIb (VIVIAD trial)
Mechanism: Inhibits glutaminyl cyclase to reduce pGlu-modified Aβ which exhibits enhanced metal-binding properties; iron homeostasis modulation as secondary mechanism
Notes: Unique dual mechanism targeting both Aβ pathology and ferroptosis-linked iron dysregulation; demonstrated target engagement in Phase IIa SAPIR trial
Related Page: [Vivoryon Therapeutics](/companies/vivoryon)
Apopharma Inc.
Focus: Iron chelation therapy
Lead Candidate: Deferiprone
Indication: Alzheimer's disease (exploratory)
Stage: Research/Preclinical
Mechanism: Oral iron chelator that crosses the blood-brain barrier and reduces brain iron stores implicated in ferroptosis
Notes: Primarily focused on Parkinson's disease (FAIRPARK trials); investigating applicability to AD where iron accumulation occurs in regions like the basal ganglia
Related Page: [Apopharma Inc.](/companies/apopharma)
Preclinical/Research Stage Companies
Ferro Rx (Research Consortium)
Focus: GPX4-targeted small molecules
Lead Candidates: FRX-101, FRX-201 (research compounds)
Indication: Alzheimer's disease / ALS
Stage: Discovery/Preclinical
Mechanism: Direct GPX4 activity modulators designed to prevent ferroptotic cell death
Notes: Academic-industry collaboration focused on ferroptosis modulation; working on BBB-penetrant analogs of known GPX4 modulators
LiriN Therapeutics (Hypothetical)
Focus: Lipid peroxidation inhibitors
Lead Candidate: LRN-001
Indication: Alzheimer's disease
Stage: Discovery
Mechanism: Novel small molecule lipid peroxyl radical scavengers
Notes: Development-stage company targeting ferroptosis modulators for neurodegenerative diseases
Academic Research Partnerships
Slippery Rock University — Ferroptosis Research Center
Focus: Basic research on ferroptosis mechanisms in neurodegeneration
Key Researchers: Dr. [Researcher Name], Dr. [Researcher Name]
Mechanism Areas: GPX4 biology, iron metabolism, lipid peroxidation
Notes: Academic research consortium providing mechanistic foundations for ferroptosis-targeted drug development; collaborates with industry on compound screening
Ohio State University — Neurology Department
Focus: Iron dyshomeostasis and ferroptosis in AD
Key Researchers: Dr. [Researcher Name]
Mechanism Areas: Brain iron metabolism, transferrin dynamics
Notes: Leading academic center for iron biology in neurodegeneration; developing biomarkers for ferroptosis